Foxconn invests US$30 million in Robocore to expand into elderly care robotics market

Projects 5X revenue growth by 2028, accelerates global market leadership and paves the way for IPO

FDA approves first immunotherapy for recurrent respiratory papillomatosis

Roche’s Susvimo maintains vision over five years

Lupin receives USFDA approvals for Liraglutide and Glucagon injectable products

Both these products will be manufactured at Lupin’s Injectable facility at Nagpur, India

Biocon Biologics expands diabetes portfolio with FDA approval of Kirsty

Briefs: Emcure Pharmaceuticals and Gland Pharma

Emcure Pharmaceuticals successfully completes USFDA PAI of Oncology facility

FDA approves Bravecto Quantum from Merck Animal Health

Seeds of Innocence launches Asia’s first at-home IVF platform

India’s fertility rate has dropped to 1.9, below the replacement level of 2.1

Alembic announces USFDA final approval for single-dose vials

Doxorubicin Hydrochloride Liposome Injection is indicated for the treatment of Ovarian Cancer, AIDS-Related Kaposi's Sarcoma, and Multiple Myeloma

European Commission approves Eylea 8 mg with extended 6-month treatment interval for nAMD and visual impairment due to DME

Eylea 8 mg is the first and only anti-vascular endothelial growth factor (VEGF) treatment in the EU with treatment intervals of up to 6 months for both patients with nAMD and DME